MMIRF (MedMira) LT-Debt-to-Total-Asset: 0.69 (As of Jan. 2026)


What is MedMira LT-Debt-to-Total-Asset?

MedMira MMIRF +302.48% LT-Debt-to-Total-Asset is 0.69 as of Jan. 2026. The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MedMira's long-term debt to total assests ratio for the quarter that ended in Jan. 2026 was 0.69.

MedMira's long-term debt to total assets ratio declined from Jan. 2025 (0.70) to Jan. 2026 (0.69). It may suggest that MedMira is progressively becoming less dependent on debt to grow their business.

MedMira  (OTCPK:MMIRF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MedMira LT-Debt-to-Total-Asset Related Terms

MedMira LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for MedMira's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira LT-Debt-to-Total-Asset Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.54 0.81 0.52 1.15

MedMira Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.95 1.15 0.68 0.69

MedMira LT-Debt-to-Total-Asset Calculation

MedMira's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2025 is calculated as

LT Debt to Total Assets (A: Jul. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jul. 2025 )/Total Assets (A: Jul. 2025 )
=3.086/2.689
=1.15

MedMira's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (Q: Jan. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2026 )/Total Assets (Q: Jan. 2026 )
=1.799/2.598
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.69 mean?
MedMira (MMIRF) has a LT-Debt-to-Total-Asset of 0.69 as of Jan. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MedMira and its competitors.
Is MedMira's LT-Debt-to-Total-Asset too high?
MedMira's current LT-Debt-to-Total-Asset is 0.69.
How does MedMira's LT-Debt-to-Total-Asset compare to VRTX and REGN?
MedMira's LT-Debt-to-Total-Asset of 0.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MedMira and its competitors. MedMira's current LT-Debt-to-Total-Asset is 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current LT-Debt-to-Total-Asset of 0.69. The current LT-Debt-to-Total-Asset is 0.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For MedMira (MMIRF), the current LT-Debt-to-Total-Asset is 0.69 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.